Cargando…
Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis?
Genetic and epigenetic factors have an important role during the development of osteoporosis. Receptor activator of nuclear factor-κ B (NF-κB) (RANK)/receptor activator of NF-κB ligand (RANKL) pathway is important for the bone remodeling, and NFATC1 and FOS are the downtargets of this pathway. Here,...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009562/ https://www.ncbi.nlm.nih.gov/pubmed/33816070 http://dx.doi.org/10.2478/bjmg-2020-0021 |
_version_ | 1783672899346890752 |
---|---|
author | Kalkan, R Tosun, O |
author_facet | Kalkan, R Tosun, O |
author_sort | Kalkan, R |
collection | PubMed |
description | Genetic and epigenetic factors have an important role during the development of osteoporosis. Receptor activator of nuclear factor-κ B (NF-κB) (RANK)/receptor activator of NF-κB ligand (RANKL) pathway is important for the bone remodeling, and NFATC1 and FOS are the downtargets of this pathway. Here, we report methylation status of NFATC1 and FOS genes in post- and premenopausal women. In this study, 30 premenopausal and 35 postmenopausal women were included. Methylation sensitive-high resolution melting (MS-HRM) analysis was used for identification of NFATC1 and FOS genes methylation. The NFATC1 gene was methylated in 11 of the 35 postmenopausal women, and the FOS gene was methylated in six of the postmenopausal women (p >0.005). Here, we found statistically significant association between unmethylation of the NFATC1 gene and postmenopausal status. This result explains the epigenetic regulation of osteoclasts during the menopausal transition, and for the first time, our results can be used for epigenetic explanation of postmenopausal osteoporosis in the literature. However, the limited number of studies in this field makes our results crucial. Our results showed great value of epigenetic profiles of postmenopausal women. |
format | Online Article Text |
id | pubmed-8009562 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Sciendo |
record_format | MEDLINE/PubMed |
spelling | pubmed-80095622021-04-02 Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis? Kalkan, R Tosun, O Balkan J Med Genet Original Article Genetic and epigenetic factors have an important role during the development of osteoporosis. Receptor activator of nuclear factor-κ B (NF-κB) (RANK)/receptor activator of NF-κB ligand (RANKL) pathway is important for the bone remodeling, and NFATC1 and FOS are the downtargets of this pathway. Here, we report methylation status of NFATC1 and FOS genes in post- and premenopausal women. In this study, 30 premenopausal and 35 postmenopausal women were included. Methylation sensitive-high resolution melting (MS-HRM) analysis was used for identification of NFATC1 and FOS genes methylation. The NFATC1 gene was methylated in 11 of the 35 postmenopausal women, and the FOS gene was methylated in six of the postmenopausal women (p >0.005). Here, we found statistically significant association between unmethylation of the NFATC1 gene and postmenopausal status. This result explains the epigenetic regulation of osteoclasts during the menopausal transition, and for the first time, our results can be used for epigenetic explanation of postmenopausal osteoporosis in the literature. However, the limited number of studies in this field makes our results crucial. Our results showed great value of epigenetic profiles of postmenopausal women. Sciendo 2021-03-23 /pmc/articles/PMC8009562/ /pubmed/33816070 http://dx.doi.org/10.2478/bjmg-2020-0021 Text en © 2020 Kalkan R, Tosun O, published by Sciendo http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. |
spellingShingle | Original Article Kalkan, R Tosun, O Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis? |
title | Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis? |
title_full | Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis? |
title_fullStr | Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis? |
title_full_unstemmed | Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis? |
title_short | Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis? |
title_sort | do we use methylation of nfatc1 and fos genes as a biomarker for postmenopausal osteoporosis? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009562/ https://www.ncbi.nlm.nih.gov/pubmed/33816070 http://dx.doi.org/10.2478/bjmg-2020-0021 |
work_keys_str_mv | AT kalkanr doweusemethylationofnfatc1andfosgenesasabiomarkerforpostmenopausalosteoporosis AT tosuno doweusemethylationofnfatc1andfosgenesasabiomarkerforpostmenopausalosteoporosis |